Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KGF-HS for Prevention of Chemotherapy-Induced Alopecia
NCT04554732Phase 1Completed
- Sponsor
- University of Arizona
- Start
- Apr 2020
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of palifermin in Chemotherapy-induced alopecia (CIA), sponsored by University of Arizona. Primary endpoint: Hair loss (CTCAE v4.0) at 4 months. Started Apr 2020; status: completed.
02
Drugs
palifermin
03
Conditions
Chemotherapy-induced alopecia (CIA)
Beyond the preview
Go deeper on NCT04554732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554732.